[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602879":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":36,"centralContacts":37,"locations":46,"responsibleParty":263,"collaborators":36,"id":265,"slug":36,"hasResults":266,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":266,"sex":272,"minAge":273,"maxAge":36,"enrollmentInfo":274,"targetDuration":36,"studyType":277,"phases":278,"briefSummary":281,"conditions":282,"keywords":286,"overallStatus":49,"whyStopped":36,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":312},{"fullName":5,"class":6},"Crinetics Pharmaceuticals Inc.","INDUSTRY",[8,14,18,22,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Escalation","EXPERIMENTAL","Multiple Dose Levels administered Q3W",[13],"Drug: CRN09682",{"label":15,"type":10,"description":16,"interventionNames":17},"Dose Expansion: Cohort 1","Pancreatic Neuroendocrine Tumor (NET)",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Dose Expansion: Cohort 2","Non-Pancreatic NET",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Dose Expansion: Cohort 3","Neuroendocrine Carcinoma (NEC)",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Dose Expansion: Cohort 4","Other Solid Tumors",[13],[31],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"DRUG","CRN09682","Study drug CRN09682 intravenously",[9,15,19,23,27],null,[38,43],{"name":39,"role":40,"phone":41,"phoneExt":36,"email":42},"Contact if you are a potential participant or caregiver","CONTACT","833-827-9741","studyinfo@crinetics.com",{"name":44,"role":40,"phone":41,"phoneExt":36,"email":45},"Contact if you are an HCP\u002Fclinical site staff\u002Fother","clinicalsites@crinetics.com",[47,60,69,77,85,93,102,111,120,129,138,146,154,163,171,180,185,194,202,210,219,228,236,245,250,258],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":36},"Crinetics Study Site","RECRUITING","Phoenix","Arizona","85054","United States",{"type":55,"coordinates":56},"Point",[57,58],-112.07404,33.44838,{"lat":58,"lon":57},{"facility":48,"status":49,"city":61,"state":62,"zip":63,"country":53,"cosmosGeoPoint":64,"geoPoint":68,"contacts":36},"Duarte","California","91010",{"type":55,"coordinates":65},[66,67],-117.97729,34.13945,{"lat":67,"lon":66},{"facility":48,"status":49,"city":70,"state":62,"zip":71,"country":53,"cosmosGeoPoint":72,"geoPoint":76,"contacts":36},"Newport Beach","92663",{"type":55,"coordinates":73},[74,75],-117.92895,33.61891,{"lat":75,"lon":74},{"facility":48,"status":49,"city":78,"state":62,"zip":79,"country":53,"cosmosGeoPoint":80,"geoPoint":84,"contacts":36},"Orange","92868",{"type":55,"coordinates":81},[82,83],-117.85311,33.78779,{"lat":83,"lon":82},{"facility":48,"status":49,"city":86,"state":62,"zip":87,"country":53,"cosmosGeoPoint":88,"geoPoint":92,"contacts":36},"San Francisco","60637",{"type":55,"coordinates":89},[90,91],-122.41942,37.77493,{"lat":91,"lon":90},{"facility":48,"status":49,"city":94,"state":95,"zip":96,"country":53,"cosmosGeoPoint":97,"geoPoint":101,"contacts":36},"Denver","Colorado","80218",{"type":55,"coordinates":98},[99,100],-104.9847,39.73915,{"lat":100,"lon":99},{"facility":48,"status":49,"city":103,"state":104,"zip":105,"country":53,"cosmosGeoPoint":106,"geoPoint":110,"contacts":36},"New Haven","Connecticut","48201",{"type":55,"coordinates":107},[108,109],-72.92816,41.30815,{"lat":109,"lon":108},{"facility":48,"status":49,"city":112,"state":113,"zip":114,"country":53,"cosmosGeoPoint":115,"geoPoint":119,"contacts":36},"Atlanta","Georgia","30322",{"type":55,"coordinates":116},[117,118],-84.38798,33.749,{"lat":118,"lon":117},{"facility":48,"status":49,"city":121,"state":122,"zip":123,"country":53,"cosmosGeoPoint":124,"geoPoint":128,"contacts":36},"Lexington","Kentucky","40536",{"type":55,"coordinates":125},[126,127],-84.47772,37.98869,{"lat":127,"lon":126},{"facility":48,"status":49,"city":130,"state":131,"zip":132,"country":53,"cosmosGeoPoint":133,"geoPoint":137,"contacts":36},"Metairie","Louisiana","70006",{"type":55,"coordinates":134},[135,136],-90.15285,29.98409,{"lat":136,"lon":135},{"facility":48,"status":49,"city":139,"state":140,"zip":105,"country":53,"cosmosGeoPoint":141,"geoPoint":145,"contacts":36},"Detroit","Michigan",{"type":55,"coordinates":142},[143,144],-83.04575,42.33143,{"lat":144,"lon":143},{"facility":48,"status":49,"city":147,"state":140,"zip":148,"country":53,"cosmosGeoPoint":149,"geoPoint":153,"contacts":36},"Grand Rapids","49503",{"type":55,"coordinates":150},[151,152],-85.66809,42.96336,{"lat":152,"lon":151},{"facility":48,"status":49,"city":155,"state":156,"zip":157,"country":53,"cosmosGeoPoint":158,"geoPoint":162,"contacts":36},"Rochester","Minnesota","53905",{"type":55,"coordinates":159},[160,161],-92.4699,44.02163,{"lat":161,"lon":160},{"facility":48,"status":49,"city":164,"state":164,"zip":165,"country":53,"cosmosGeoPoint":166,"geoPoint":170,"contacts":36},"New York","10016",{"type":55,"coordinates":167},[168,169],-74.00597,40.71427,{"lat":169,"lon":168},{"facility":48,"status":49,"city":172,"state":173,"zip":174,"country":53,"cosmosGeoPoint":175,"geoPoint":179,"contacts":36},"Philadelphia","Pennsylvania","19104",{"type":55,"coordinates":176},[177,178],-75.16362,39.95238,{"lat":178,"lon":177},{"facility":48,"status":49,"city":172,"state":173,"zip":181,"country":53,"cosmosGeoPoint":182,"geoPoint":184,"contacts":36},"19111",{"type":55,"coordinates":183},[177,178],{"lat":178,"lon":177},{"facility":48,"status":49,"city":186,"state":187,"zip":188,"country":53,"cosmosGeoPoint":189,"geoPoint":193,"contacts":36},"Austin","Texas","78758",{"type":55,"coordinates":190},[191,192],-97.74306,30.26715,{"lat":192,"lon":191},{"facility":48,"status":49,"city":195,"state":187,"zip":196,"country":53,"cosmosGeoPoint":197,"geoPoint":201,"contacts":36},"Houston","70030",{"type":55,"coordinates":198},[199,200],-95.36327,29.76328,{"lat":200,"lon":199},{"facility":48,"status":49,"city":203,"state":187,"zip":204,"country":53,"cosmosGeoPoint":205,"geoPoint":209,"contacts":36},"Irving","75039",{"type":55,"coordinates":206},[207,208],-96.94889,32.81402,{"lat":208,"lon":207},{"facility":48,"status":49,"city":211,"state":212,"zip":213,"country":53,"cosmosGeoPoint":214,"geoPoint":218,"contacts":36},"Salt Lake City","Utah","84112",{"type":55,"coordinates":215},[216,217],-111.89105,40.76078,{"lat":217,"lon":216},{"facility":48,"status":49,"city":220,"state":221,"zip":222,"country":53,"cosmosGeoPoint":223,"geoPoint":227,"contacts":36},"Charlottesville","Virginia","22908",{"type":55,"coordinates":224},[225,226],-78.47668,38.02931,{"lat":226,"lon":225},{"facility":48,"status":49,"city":229,"state":221,"zip":230,"country":53,"cosmosGeoPoint":231,"geoPoint":235,"contacts":36},"Fairfax","22031",{"type":55,"coordinates":232},[233,234],-77.30637,38.84622,{"lat":234,"lon":233},{"facility":48,"status":49,"city":237,"state":36,"zip":238,"country":239,"cosmosGeoPoint":240,"geoPoint":244,"contacts":36},"Barcelona","08023","Spain",{"type":55,"coordinates":241},[242,243],2.15899,41.38879,{"lat":243,"lon":242},{"facility":48,"status":49,"city":237,"state":36,"zip":246,"country":239,"cosmosGeoPoint":247,"geoPoint":249,"contacts":36},"08035",{"type":55,"coordinates":248},[242,243],{"lat":243,"lon":242},{"facility":48,"status":49,"city":251,"state":36,"zip":252,"country":239,"cosmosGeoPoint":253,"geoPoint":257,"contacts":36},"Madrid","28040",{"type":55,"coordinates":254},[255,256],-3.70256,40.4165,{"lat":256,"lon":255},{"facility":48,"status":49,"city":251,"state":36,"zip":259,"country":239,"cosmosGeoPoint":260,"geoPoint":262,"contacts":36},"28041",{"type":55,"coordinates":261},[255,256],{"lat":256,"lon":255},{"type":264,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR","100602879",false,"NCT07129252","A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors","A Phase 1\u002F2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants With Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors","BRAVESST2","Inclusion Criteria:\n\n* Have a histological diagnosis of metastatic or locally advanced inoperable NET, NEC, or other solid tumors that have confirmed radiological progression.\n* Have one or more measurable disease location per RECIST version 1.1.\n* Have a tumor that expresses SSR confirmed by SSR imaging.\n* Have an ECOG performance status of 0, 1, or 2.\n\nExclusion Criteria:\n\n* Have tumor progression while undergoing a course of PRRT or within 6 months of completing PRRT.\n* Have brain metastases unless asymptomatic and stable for at least one month for participants with SCLC or LCLC or at least 3 months for participants with other non-NET solid tumors.\n* Use of anticancer agents within specified intervals prior to the first dose of study drug.\n* Had surgery, chemoembolization, or radiofrequency ablation within 90 days prior to first dose of study drug.\n* Prior participation in any intervention clinical study within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study drug.\n* Participants with carcinoid syndrome.\n* Secondary malignancy: participants who have any other malignancy known to be active or treated within 3 years of the start of screening, with the exception of treated cervical intraepithelial neoplasia, superficial (noninvasive) bladder cancer, and non-melanoma skin cancer.\n* Have prior treatment with MMAE.\n* Have hypersensitivity or history of anaphylactic reaction to octreotide, other SSAs, and\u002For MMAE.","ALL","18 Years",{"count":275,"type":276},150,"ESTIMATED","INTERVENTIONAL",[279,280],"PHASE1","PHASE2","This Phase 1\u002F2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD identification, additional participants will be enrolled at the expansion dose to further assess safety, tolerability, PK, and antitumor activity.",[283,284,285],"SST2-positive Neuroendocrine Neoplasms","Neuroendocrine Tumors","Neuroendocrine Neoplasm",[33,287,285,288,289,290,291,292,293,294,295,9,296,297,298,299,300,301,302],"Crinetics","NEN","Neuroendocrine Tumor","NET","MMAE","SST2","Somatostatin","Metastatic","Solid Tumor","Dose Expansion","Phase 1","SSTR+","Phase 2","Phase 1\u002F2","Neuroendocrine Carcinoma","NEC","2026-06-30",{"date":305,"type":306},"2026-07-01","ACTUAL",{"date":308,"type":306},"2025-11-26",{"date":310,"type":276},"2029-08",{"name":5,"class":6},26]